Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Scholar Rock set a $11,659 list price per single-use vial for its newly approved spinal muscular atrophy drug. The therapy is the first approved treatment to directly target muscle loss in patients with the rare genetic disorder, creating a differentiated commercial opportunity for the company.